Just Released: "Market and Product Forecasts: Asthma - Premium products to offset loss to generics"

New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research
By: Fast Market Research, Inc.
Oct. 4, 2012 - PRLog -- The asthma market has seen strong growth, with increased uptake of relatively expensive combination products. This trend is expected to change in the near future as sales growth will slow, and even turn negative, as key products face generic entry. However, by 2021, Datamonitor forecasts a return to positive growth such that the market will maintain value, with a CAGR over 2012-21 of 0.1%.

* Access Datamonitor's patient-based asthma market forecast for the seven major markets, with transparent methodology and clear assumptions.
* Understand how market dynamics are changing and which drug classes will be most impacted in the next 10 years.
* Gain insight into how late-stage pipeline products will change the market and which currently marketed products are insulated against brand erosion.
* See how generics will impact the asthma market and gain insight into which drug classes are the most vulnerable.

Full Report Details at
- http://www.fastmr.com/prod/464850_market_and_product_fore...


Datamonitor forecasts four new product launches in asthma over the next 10 years. New products for asthma across the seven major markets will counteract generic erosion and help the market to maintain value. Datamonitor forecasts the asthma market to increase from $15.0bn in 2012 to $15.1bn by 2021, representing a 2012-21 CAGR of 0.1%.

The impact of generics will vary considerably by drug class. The antileukotriene class is expected to see a rapid decline as Singulair succumbs to generic entry. However, Datamonitor expects a relatively low impact of generics on inhaled combination products, although price discounting and patient switching will vary by country.

While the ICS/LABA class will remain unrivalled as the most profitable in asthma, it will see significant changes. The first ICS/LABA generics are expected to enter the market from 2013. However, greater patient switching is expected from current market leaders to the first once-daily ICS/LABAs, than to generics.

Reasons to Get this Report
* How can generics compete with new product launches in the ICS/LABA class?
* How will current market leaders be impacted by additional product launches and which products will resist brand erosion?
* How are class dynamics changing in asthma and which drug classes will be the most profitable in 2021?
* How do asthma markets differ across the seven major markets and how will these markets react to events over the next 10 years?

Partial Table of Contents:


* Catalyst
* Summary


* Strategic scoping and focus
* Datamonitor key findings


* Market definition for asthma

* Long-acting beta 2 agonists + inhaled corticosteroids (R3F1)
* Long-acting beta 2 agonists (R3A3)
* Short-acting beta 2 agonists (R3A4)
* Inhaled corticosteroids (R3D1)
* Antileukotrienes (R3J2)
* All other asthma and chronic obstructive pulmonary disease (R3X2)

* Forecast methodology and assumptions

* Methodology flow
* Patent expiries
* New product launches


* Current and future market dynamics overview

* Generic erosion to cause short-term market decline
* ICS/LABAs to maintain dominance despite in-class changes
* Marginal growth forecast for the US market
* The Japanese asthma market faces a turbulent 10 years
* Asthma markets to stagnate in the EU
* France
* Germany
* Italy
* Spain
* UK


* Advair (fluticasone/salmeterol; GlaxoSmithKline)

* Forecast assumptions
* Advair forecast 2012aEUR"21

* Singulair (montelukast; Merck & Co.)

* Forecast assumptions
* Singulair forecast 2012aEUR"21

* Symbicort (budesonide/formoterol; AstraZeneca)

* Forecast assumptions
* Symbicort forecast 2012aEUR"21

* Dulera (mometasone/formoterol; Merck & Co.)

* Forecast assumptions
* Dulera forecast 2012aEUR"21

* Xolair (omalizumab; Genentech/Roche/Novartis)

* Forecast assumptions
* Xolair forecast 2012aEUR"21

* Flutiform (fluticasone/formoterol; SkyePharma)

* Forecast assumptions
* Flutiform forecast 2012aEUR"21

* Relovair (Breo/Relvar, fluticasone furoate/vilanterol; GlaxoSmithKline)

* Forecast assumptions
* Relovair forecast 2012aEUR"21

* QMF149 (mometasone/indacaterol; Novartis)

* Forecast assumptions
* QMF149 forecast 2012aEUR"21

* Lebrikizumab (Genentech/Roche)

* Forecast assumptions
* Lebrikizumab forecast 2012aEUR"21


* Websites
* Datamonitor reports


* Contributing experts
* Forecast methodology

* Volume and value forecast methodology
* Physician sample breakdown


* Table: Price sources and calculations, by country, 2012
* Table: Exchange rates used for calculating prices, 2012
* Table: Patent expiry dates for key marketed brands in asthma, by country, 2012
* Table: Launch dates for asthma pipeline products, 2012aEUR"21
* Table: Asthma brand sales in the seven major markets ($m), 2012aEUR"21
* Table: DatamonitoraEURs price assumptions for Advair, 2012
* Table: Advair (fluticasone/salmeterol; GlaxoSmithKline) forecast sales for asthma in the seven major markets, by device ($m), 2012aEUR"21
* Table: DatamonitoraEURs price assumptions for Singulair, 2012
* Table: Singulair (montelukast; Merck & Co.) forecast sales for asthma in the seven major markets ($m), 2012aEUR"21
* Table: DatamonitoraEURs price assumptions for Symbicort

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4648...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.
Email:***@fastmr.com Email Verified
Tags:Asthma, 2012aeur21, Assumptions
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Most Viewed
Daily News

Like PRLog?
Click to Share